Literature DB >> 1517777

PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.

T Lotta1, J Taskinen, R Bäckström, E Nissinen.   

Abstract

Quantitative structure-activity analysis was carried out for in vitro inhibition of rat brain soluble catechol O-methyltransferase by a series (N = 99) of 1,5-substituted-3,4-dihydroxybenzenes using computational chemistry and multivariate PLS modelling of data sets. The molecular structural descriptors (N = 19) associated with the electronics of the catecholic ring and sizes of substituents were derived theoretically. For the whole set of molecules two separate PLS models have to be used. A PLS model with two significant (crossvalidated) model dimensions describing 82.2% of the variance in inhibition activity data was capable of predicting all molecules except those having the largest R1 substituent or having a large R5 substituent compared to the NO2 group. The other PLS model with three significant (crossvalidated) model dimensions described 83.3% of the variance in inhibition activity data. This model could not handle compounds having a small R5 substituent, compared to the NO2 group, or the largest R1 substituent. The predictive capability of these PLS models was good. The models reveal that inhibition activity is nonlinearly related to the size of the R5 substituent. The analysis of the PLS models also shows that the binding affinity is greatly dependent on the electronic nature of both R1 and R5 substituents. The electron-withdrawing nature of the substituents enhances inhibition activity. In addition, the size of the R1 substituent and its lipophilicity are important in the binding of inhibitors. The size of the R1 substituent has an upper limit. On the other hand, ionized R1 substituents decrease inhibition activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517777     DOI: 10.1007/bf00123380

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  14 in total

Review 1.  Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Authors:  H C Guldberg; C A Marsden
Journal:  Pharmacol Rev       Date:  1975-06       Impact factor: 25.468

2.  Enzymatic O-methylation of epinephrine and other catechols.

Authors:  J AXELROD; R TOMCHICK
Journal:  J Biol Chem       Date:  1958-09       Impact factor: 5.157

Review 3.  New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

Authors:  P T Männistö; S Kaakkola
Journal:  Trends Pharmacol Sci       Date:  1989-02       Impact factor: 14.819

4.  Purification and partial characterization of rat liver soluble catechol-O-methyltransferase.

Authors:  C Tilgmann; N Kalkkinen
Journal:  FEBS Lett       Date:  1990-05-07       Impact factor: 4.124

5.  Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.

Authors:  I B Lindén; E Nissinen; E Etemadzadeh; S Kaakkola; P Männistö; P Pohto
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

6.  Interactions between estrogens and catechol amines. 3. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the ctechol-O-methyltransferases of human liver.

Authors:  P Ball; R Knuppen; M Haupt; H Breuer
Journal:  J Clin Endocrinol Metab       Date:  1972-04       Impact factor: 5.958

7.  Presence of two distinct catechol -O- methyltransferase activities in red blood cells.

Authors:  M Assicot; C Bohuon
Journal:  Biochimie       Date:  1971       Impact factor: 4.079

8.  Peptide quantitative structure-activity relationships, a multivariate approach.

Authors:  S Hellberg; M Sjöström; B Skagerberg; S Wold
Journal:  J Med Chem       Date:  1987-07       Impact factor: 7.446

9.  Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.

Authors:  R Bäckström; E Honkanen; A Pippuri; P Kairisalo; J Pystynen; K Heinola; E Nissinen; I B Linden; P T Männistö; S Kaakkola
Journal:  J Med Chem       Date:  1989-04       Impact factor: 7.446

10.  Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form.

Authors:  B Bertocci; V Miggiano; M Da Prada; Z Dembic; H W Lahm; P Malherbe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  4 in total

1.  Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.

Authors:  P Lautala; M Kivimaa; H Salomies; E Elovaara; J Taskinen
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

2.  A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols.

Authors:  M Ovaska; A Yliniemelä
Journal:  J Comput Aided Mol Des       Date:  1998-05       Impact factor: 3.686

3.  A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods.

Authors:  Anu J Tervo; Tommi H Nyrönen; Toni Rönkkö; Antti Poso
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

4.  Drug design for ever, from hype to hope.

Authors:  G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Journal:  J Comput Aided Mol Des       Date:  2012-01-18       Impact factor: 3.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.